At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Gemcitabine, Capecitabine and Bevacizumabdrug
Likely dose
Gemcitabine, Capecitabine and Bevacizumab 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts.
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Capecitabine and Bevacizumab for Cholangiocarcinoma. Completed, enrolled 50 participants across 2 sites.
Detailed Summary
To assess the proposed therapy for patients with advanced gallbladder or biliary cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartDec 2009
Primary CompletionMay 2015
TodayJul 2026
First PostedNov 4, 2009
Enrollment StartDec 1, 2009
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 16.7 years ago
Interventions
Gemcitabine, Capecitabine and Bevacizumabdrug
Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.